ANTENGENE CORPORATION LIMITED SUCCESSFULLY LISTED ON HKEX
Latest Update:
20 th November, 2020

On 20 November 2020,Antengene Corporation Limited(" Antengene "or the" Company ", together with its subsidiaries, collectively referred to as the "Group";  Stock code: 6996.HK), a clinical stage biopharmaceutical company focusing on new drug development and clinical research in the Asia-Pacific region with global distribution, was officially listed and started trading on the main board of the Stock Exchange of Hong Kong Limited (" HKEX ").  

A total of 154,153,500 shares were sold in the global offering, and each share offered was ultimately sold at HK $18.08.  Net proceeds from the Global Offering are estimated to be approximately HK $2,635.9 million after deducting underwriting fees and expenses paid and payable in connection with the Global Offering.  The Hong Kong offering was well received with valid applications amounting to about 264.76 times the total number of shares available for the initial offering, while the international offering was oversubscribed by about 13.5 times.  As the Hong Kong public offering portion was substantially oversubscribed, the Company initiated a clawback mechanism to reallocation a portion of the international offering to the Hong Kong Public offering.  The final number of shares offered in the Hong Kong public offering and the international offering was 77,077,000 and 77,076,500 respectively, each representing approximately 50% of the initial number of shares available for sale under the global offering prior to the exercise of any over-allotment rights.  

Antengene focuses on innovative anti-tumor drugs, and discovers, develops and commercializes the first, the only and/or the best therapies of the same kind in the world that can cooperate with each other through the differentiated r&d strategy of "combination and complementarity", so as to fully release its therapeutic potential.  As of the last practical date, the company has built an innovative pipeline of 12 oncology drugs.  One of the company's core products, ATG-010 (Selinexor), or XPOVIO® (Selinexor), is the first and only (SINE) compound of its kind that inhibits nuclear output protein XPO1, which promotes the accumulation of tumor suppressor protein in the nucleus and selectively induces apoptosis of cancer cells.  Currently, the company has conducted two phase II registered clinical trials in China for the treatment of relapsed/refractory multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma, combined with data from the clinical trials conducted by Karyopharm, a nasdaq-listed commercial stage pharmaceutical company.  A New Drug Marketing application (NDA) for ATG-010 (Selinexor) will be submitted directly on or before 2021 in a number of Asia-pacific countries or regions where there is a chance of obtaining NDA approval without additional trials, including Australia, Singapore, Hong Kong, South Korea, Taiwan and Thailand.  

Dr. Jianming Mei, founder of Antengene, has more than 25 years of experience in global oncology clinical research and development. Other members of the management team also have outstanding achievements in drug research, clinical development, commercialization, financing and investment.  With a high quality and experienced management team, the company since its establishment, has won industry leading investors (including new strategic investors, yao Ming Kant and tiger medicine) and financial investors (including fidelity funds, the government of Singapore investment corporation, blackrock, hillhouse capital and tongxie decoction, abundant capital, capital, qiming, etc.).  In addition, Fidelity Funds, GIC, BlackRock, Boyu Capital, Cormorant, Hillhouse Capital, Sequoia Capital China Fund, Morning Ridge Capital, Laurion Capital Master Fund and Octagon Investments are cornerstone investors in the global offering.  

Dr. Jianming Mei, Founder, Chairman and CEO of Antengene said:  "Today marks a significant milestone in Antengene's development. Antengene's successful listing on the Hong Kong stock market reflects global investors' recognition of our strategic model, growth potential, management team and product pipeline. We are proud of this and very grateful to investors for their trust and support for Antengene.  Based on the new starting point, we will seize the historical opportunity of global innovative drug development, through differentiated development strategies, seize the most cutting-edge RESEARCH and development hot spots, and continue to discover, develop and commercialize new anti-tumor innovative therapies with new mechanisms of action, to address the unmet clinical needs of patients in the Asia-pacific and the world."  

About Antengene Corporation Limited  

Antengene Corporation Limited is an Asia-pacific clinical-stage biopharmaceutical company focused on innovative anticancer drugs that provide novel mechanisms of action for patients in the Asia-pacific region and around the world.  Since its inception, Antengene has established a rich pipeline of 12 clinical and preclinical innovative drugs, obtained 9 clinical approvals, and conducted 9 cross-regional clinical trials in the Asia-pacific region.  The company is developing products that focus on innovative targets or mechanisms of action and have the potential to be the first drug in its class.  Antengene people, with the vision of "medical boundless, sustainable innovation", strives to solve the unmet clinical needs of patients in the Asia-Pacific and even the world through the global initiative and the best of the same kind of specialized research and marketing. 

Latest Update:
20 th November, 2020